# A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

> **NCT04504825** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 125 (actual)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** CAEL-101
- **OTHER:** Placebo
- **DRUG:** cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen

## Key facts

- **NCT ID:** NCT04504825
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-25
- **Primary completion:** 2025-05-10
- **Final completion:** 2027-10-22
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504825, "A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04504825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*